Annual report pursuant to Section 13 and 15(d)

Schedule of Reconciliation of Segment Performance (Details)

v3.10.0.1
Schedule of Reconciliation of Segment Performance (Details) - USD ($)
$ in Thousands
12 Months Ended
Nov. 30, 2018
Nov. 30, 2017
Segment Performance $ (12,743) $ (8,149)
Stock-based compensation (4,364) (3,364)
Financial income (expenses), net (2,938) (950)
Net gain on remeasurement of previously equity interest in Atvio and CureCell to acquisition date fair value 4,509 0
Transaction expenses related to GPP agreement (1,500)  
Share in losses of associated companies (731) (1,214)
Loss before income tax $ (17,767) $ (13,677)